A new comprehensive colorectal cancer risk prediction model incorporating family history, personal characteristics, and environmental factors
- 期刊名称Cancer Epidemiology Biomarkers & Prevention
- 作者Zheng, Yingye; Hua, Xinwei; Win, Aung K; MacInnis, Robert J.; Gallinger, Steven; Le Marchand, Loic; Lindor, Noralane M.; Baron, John A.; Hopper, John L.; Dowty, James G; Antoniou, Antonis C.; Zheng, Jiayin; Jenkins, Mark A; Newcomb, Polly A.
- 印刷ISSN1055-9965
- 电子ISSN1538-7755
- 文件大小1554.76KB
- 发表时间2020-01-13
- DOI10.1158/1055-9965.epi-19-0929
263 A study of capecitabine in elderly patients as first line treatment in advanced or metastatic colorectal cancerJ. Feliu; P. Escudero; F. Losa; M. Bolaños; J. Vicent; A. Yubero; J. Sanz-Lacalle; R. López; L. López-Gómez; M. González-Barón · 2003
277 Combination of irinotecan and capecitabine as first line treatment in advanced colorectal cancer (ACC): results of a phase II multicenter trialC.J.A. Punt; J.W.R. Nortier; W.W. ten Bokkel Huinink; S. Falk; D.J. Richel; T. Maughan; G. Groenewegen; J.M. Smith; J.M. Bakker; D.W. Rea · 2003
Bi-weekly administration of capecitabine + oxaliplatin (XELOX-2) in first line treatment of advanced colorectal cancer (ACRC): Preliminary resultsM. Di Bisceglie; G. Di Maggio; F. Giuliani; V. Lorusso; S. Cinieri; G. Colucci; E. Maiello · 2008
Phase III trial of 5-fluorouracil (5FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first line treatment in advanced colorectal cancer (ACC)C.J.A. Punt; H.J. Keizer; J. Douma; J. Schüller; T. Skovsgaard; C.H.H. ten Napel; H. Lochs; E.W. Muller; L. Russell; D.J.T. Wagener · 1999
A phase II study of biweekly irinotecan (CPT-11) and 5-fluorouracil (5-FU) as first line treatment in advanced or metastatic colorectal cancer (CRC)Salvador, J.; Bernabe, R.; Bolaños, M.; Borrega, P.; Valladares, M.; Cobo, M.; Reina, J.; Gomez-Reina, M.; Gallurt, P.; Moreno-Nogueira, J. · European Journal of Cancer · 2001
A phase II study of weekly irinotecan (CPT-11) and oral uracil and ftorafur (UFT) plus folinic acid (FA) as first line treatment in advanced colorectal cancer (CRC)Cruz, J.; Mendez, M.; Alfonso, P.; Gonzalez, E.; Pujol, E.; Castañon, C.; Cerezuela, P. · European Journal of Cancer · 2001
Mismatch Repair Deficiency, Microsatellite Instability, and SurvivalSmyth, Elizabeth C.; Wotherspoon, Andrew; Peckitt, Clare; Gonzalez, David; Hulkki-Wilson, Sanna; Eltahir, Zakaria; Fassan, Matteo; Rugge, Massimo; Valeri, Nicola; Okines, Alicia; Hewish, Madeleine; Allum, William; Stenning, Sally; Nankivell, Matthew; Langley, Ruth; Cunningham, David · JAMA Oncology · 2017
Mismatch repair deficient colorectal cancer in the era of personalized treatmentHewish, Madeleine; Lord, Christopher J.; Martin, Sarah A.; Cunningham, David; Ashworth, Alan · Nature Reviews Clinical Oncology · 2010
Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer MedicineHewish, Madeleine; Chau, Ian; Cunningham, David · Recent Patents on Anti-Cancer Drug Discovery · 2009